Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

PERRY SHIEH

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1588683395
CMS profile
253101
Location
LOS ANGELES, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$392,194.79

386 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

By paying entity

PY2022 · entire year · sorted by reported total

Page 2 of 8; records 51–100 of 386 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

PERRY SHIEH

NPI 1588683395 · CMS profile ID 253101

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

LOS ANGELES, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 8; records 51–100 of 386 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1588683395?year=2022&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
PERRY SHIEH, NPI 1588683395, CMS profile ID 253101. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 8; records 51–100 of 386 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1588683395?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). PERRY SHIEH, NPI 1588683395, CMS profile ID 253101. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 8; records 51–100 of 386 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1588683395?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
PERRY SHIEH, NPI 1588683395, CMS profile ID 253101, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 8; records 51–100 of 386 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1588683395?year=2022&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

386 matching records · $392,194.79 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 386 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 386.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
ARGENX US, INC. $3,162.5010/26/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 951632367 CMS
ARGENX US, INC. $181.6910/26/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 951632369 CMS
ARGENX US, INC. $143.8710/26/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 951632371 CMS
Alexion Pharmaceuticals, Inc. $14.9310/25/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915783417 CMS
Sarepta Therapeutics, Inc. $11,275.0010/21/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 946453941 CMS
Biogen, Inc. $23.1510/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923421141 CMS
Biogen, Inc. $1,839.0010/14/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923462719 CMS
Sarepta Therapeutics, Inc. $10.9310/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 946453955 CMS
Sarepta Therapeutics, Inc. $14.9510/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 946453957 CMS
Biogen, Inc. $90.5410/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923418515 CMS
F. Hoffmann-La Roche AG $101.8010/13/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950808609 CMS
F. Hoffmann-La Roche AG $343.9110/13/2022 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950808611 CMS
F. Hoffmann-La Roche AG $46.2410/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950808613 CMS
F. Hoffmann-La Roche AG $5,175.0010/13/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950808615 CMS
Sarepta Therapeutics, Inc. $23.2410/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 946453969 CMS
Genentech USA, Inc. $93.7110/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950733313 CMS
Alexion Pharmaceuticals, Inc. $2,550.0010/11/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 914930289 CMS
GENZYME CORPORATION $2,804.0010/11/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938937989 CMS
Sarepta Therapeutics, Inc. $13,200.0010/11/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 946453949 CMS
Sarepta Therapeutics, Inc. $104.7610/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 946454033 CMS
Sarepta Therapeutics, Inc. $119.5810/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 946454045 CMS
Sarepta Therapeutics, Inc. $3,103.3410/09/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 946453931 CMS
Sarepta Therapeutics, Inc. $32.9610/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 946453979 CMS
Sarepta Therapeutics, Inc. $44.5610/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 946453987 CMS
Sarepta Therapeutics, Inc. $47.8810/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 946453993 CMS
Sarepta Therapeutics, Inc. $72.4710/09/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 946454015 CMS
Sarepta Therapeutics, Inc. $95.7310/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 946454023 CMS
Sarepta Therapeutics, Inc. $99.7310/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 946454027 CMS
Sarepta Therapeutics, Inc. $368.9910/09/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 946454415 CMS
Sarepta Therapeutics, Inc. $30.6210/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 946453975 CMS
CATALYST PHARMACEUTICALS, INC. $70.1410/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950295291 CMS
CATALYST PHARMACEUTICALS, INC. $587.2510/07/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950295553 CMS
CATALYST PHARMACEUTICALS, INC. $3,300.0010/07/2022 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950296635 CMS
Biogen, Inc. $1,839.0010/06/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923398475 CMS
Genentech USA, Inc. $900.1010/06/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950654737 CMS
Genentech USA, Inc. $121.9710/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950654743 CMS
Genentech USA, Inc. $4,800.0010/06/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950654745 CMS
Genentech, Inc. $55.0610/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950749503 CMS
Sarepta Therapeutics, Inc. $34.3010/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 946453981 CMS
UCB, Inc. $17.5010/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 908055281 CMS
Sarepta Therapeutics, Inc. $15.7710/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 946453961 CMS
Sarepta Therapeutics, Inc. $48.9409/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 946453997 CMS
Alexion Pharmaceuticals, Inc. $121.3009/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915765501 CMS
Biogen, Inc. $24.6609/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923407993 CMS
Genentech, Inc. $149.5109/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950759581 CMS
ARGENX US, INC. $70.8109/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 951632373 CMS
ARGENX US, INC. $45.5809/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 951632375 CMS
ARGENX US, INC. $72.8909/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 951632377 CMS
Sarepta Therapeutics, Inc. $102.5709/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 946454029 CMS
Sarepta Therapeutics, Inc. $11,540.6309/19/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 946453943 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $347,742.64 470
PY2020 $169,372.20 166
PY2021 $205,496.13 221
PY2022 $392,194.79 386
PY2023 $368,420.18 343
PY2024 $370,504.79 347
PY2025 $588,117.84 553

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $5,004.62 3
PY2025 Principal investigator $611,343.64 106
PY2024 Recipient $15,612.73 9
PY2024 Principal investigator $1,500,264.79 94
PY2023 Recipient $10,346.12 18
PY2023 Principal investigator $916,305.22 134
PY2022 Recipient $7,010.00 7
PY2022 Principal investigator $329,507.55 88
PY2021 Recipient $818.28 3
PY2021 Principal investigator $731,667.65 75
PY2020 Principal investigator $968,806.04 72
PY2019 Principal investigator $657,183.90 74

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

109 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 PFIZER INC. $4,851.00 12/24/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
LONGTERM FOLLOWUP SAFETY AND EFFICACY STUDY IN PARTICIPANTS WITH DUCHENNE MUSCULAR DYSTROPHY WHO HAVE RECEIVED FORDADISTROGENE MOVAPARVOVEC IN A PRECEDING CLINICAL STUDY No dispute reported 06/30/2026 1228816193
Principal investigator 1 PFIZER INC. $6,935.87 12/15/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
A PHASE 1B MULTICENTER OPENLABEL SINGLE ASCENDING DOSE STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF PF06939926 IN AMBULATORY AND NONAMBULATORY SUBJECTS WITH DUCHENNE MUSCULAR DYSTROPHY No dispute reported 06/30/2026 1228805875
Principal investigator 1 PFIZER INC. $6,989.72 12/15/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
A PHASE 1B MULTICENTER OPENLABEL SINGLE ASCENDING DOSE STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF PF06939926 IN AMBULATORY AND NONAMBULATORY SUBJECTS WITH DUCHENNE MUSCULAR DYSTROPHY No dispute reported 06/30/2026 1228805880
Principal investigator 1 PFIZER INC. $6,935.87 12/15/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
A PHASE 1B MULTICENTER OPENLABEL SINGLE ASCENDING DOSE STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF PF06939926 IN AMBULATORY AND NONAMBULATORY SUBJECTS WITH DUCHENNE MUSCULAR DYSTROPHY No dispute reported 06/30/2026 1228805965
Principal investigator 1 PFIZER INC. $6,130.14 12/15/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
A PHASE 1B MULTICENTER OPENLABEL SINGLE ASCENDING DOSE STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF PF06939926 IN AMBULATORY AND NONAMBULATORY SUBJECTS WITH DUCHENNE MUSCULAR DYSTROPHY No dispute reported 06/30/2026 1228805970
Principal investigator 1 Alnylam Pharmaceuticals Inc. $500.00 12/10/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
ConTTRibute: A Global Observational Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis) No dispute reported 06/30/2026 1215521958
Principal investigator 1 Sarepta Therapeutics, Inc. $1,629.61 12/05/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
SRP-9001-305 No dispute reported 06/30/2026 1223611669
Principal investigator 1 Sarepta Therapeutics, Inc. $3,908.42 12/05/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
SRP-9001-305 No dispute reported 06/30/2026 1223611671
Principal investigator 1 Sarepta Therapeutics, Inc. $3,908.42 12/05/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
SRP-9001-305 No dispute reported 06/30/2026 1223613478
Principal investigator 1 Sarepta Therapeutics, Inc. $1,629.61 12/05/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
SRP-9001-305 No dispute reported 06/30/2026 1223613480
Principal investigator 1 Sarepta Therapeutics, Inc. $3,908.42 12/05/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
SRP-9001-305 No dispute reported 06/30/2026 1223613482
Principal investigator 1 Sarepta Therapeutics, Inc. $3,908.42 12/05/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
SRP-9001-305 No dispute reported 06/30/2026 1223613484
Principal investigator 1 PTC Therapeutics, Inc. $2,205.00 11/25/2025 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
AN OPEN-LABEL, SAFETY STUDY FOR ATALUREN (PTC124) PATIENTS WITH NONSENSE MUTATION DYSTROPHINOPATHY No dispute reported 06/30/2026 1249092781
Principal investigator 1 PTC Therapeutics, Inc. $1,275.75 11/25/2025 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
AN OPEN-LABEL, SAFETY STUDY FOR ATALUREN (PTC124) PATIENTS WITH NONSENSE MUTATION DYSTROPHINOPATHY No dispute reported 06/30/2026 1249092783
Principal investigator 1 PTC Therapeutics, Inc. $19,404.00 11/25/2025 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
AN OPEN-LABEL, SAFETY STUDY FOR ATALUREN (PTC124) PATIENTS WITH NONSENSE MUTATION DYSTROPHINOPATHY No dispute reported 06/30/2026 1249092785
Principal investigator 1 PTC Therapeutics, Inc. $2,520.00 11/25/2025 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
AN OPEN-LABEL, SAFETY STUDY FOR ATALUREN (PTC124) PATIENTS WITH NONSENSE MUTATION DYSTROPHINOPATHY No dispute reported 06/30/2026 1249092787
Principal investigator 1 PFIZER INC. $15,813.56 11/14/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
A PHASE 1B MULTICENTER OPENLABEL SINGLE ASCENDING DOSE STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF PF06939926 IN AMBULATORY AND NONAMBULATORY SUBJECTS WITH DUCHENNE MUSCULAR DYSTROPHY No dispute reported 06/30/2026 1228821228
Principal investigator 1 Sarepta Therapeutics, Inc. $1,560.00 11/14/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
SRP-9001-305 No dispute reported 06/30/2026 1223611629
Principal investigator 1 Sarepta Therapeutics, Inc. $1,260.00 11/14/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
SRP-9001-305 No dispute reported 06/30/2026 1223611631
Principal investigator 1 Sarepta Therapeutics, Inc. $1,260.00 11/14/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
SRP-9001-305 No dispute reported 06/30/2026 1223611633
Principal investigator 1 Sarepta Therapeutics, Inc. $1,560.00 11/14/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
SRP-9001-305 No dispute reported 06/30/2026 1223611635
Principal investigator 1 Sarepta Therapeutics, Inc. $1,560.00 11/14/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
SRP-9001-305 No dispute reported 06/30/2026 1223611637
Principal investigator 1 Sarepta Therapeutics, Inc. $1,560.00 11/14/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
SRP-9001-305 No dispute reported 06/30/2026 1223611639
Principal investigator 1 Sarepta Therapeutics, Inc. $780.00 11/14/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
SRP-9001-305 No dispute reported 06/30/2026 1223611641
Principal investigator 1 Sarepta Therapeutics, Inc. $1,560.00 11/14/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
SRP-9001-305 No dispute reported 06/30/2026 1223611643
Principal investigator 1 Sarepta Therapeutics, Inc. $1,260.00 11/14/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
SRP-9001-305 No dispute reported 06/30/2026 1223611645
Principal investigator 1 Sarepta Therapeutics, Inc. $1,260.00 11/14/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
SRP-9001-305 No dispute reported 06/30/2026 1223611647
Principal investigator 1 Sarepta Therapeutics, Inc. $1,560.00 11/14/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
SRP-9001-305 No dispute reported 06/30/2026 1223611649
Principal investigator 1 Sarepta Therapeutics, Inc. $1,560.00 11/14/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
SRP-9001-305 No dispute reported 06/30/2026 1223614381
Principal investigator 1 Sarepta Therapeutics, Inc. $1,560.00 11/14/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
SRP-9001-305 No dispute reported 06/30/2026 1223614383
Principal investigator 1 Sarepta Therapeutics, Inc. $1,560.00 11/14/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
SRP-9001-305 No dispute reported 06/30/2026 1223614385
Principal investigator 1 Sarepta Therapeutics, Inc. $1,560.00 11/14/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
SRP-9001-305 No dispute reported 06/30/2026 1223614387
Principal investigator 1 Sarepta Therapeutics, Inc. $1,560.00 11/14/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
SRP-9001-305 No dispute reported 06/30/2026 1223614389
Principal investigator 1 Sarepta Therapeutics, Inc. $1,260.00 11/14/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
SRP-9001-305 No dispute reported 06/30/2026 1223614391
Principal investigator 1 Sarepta Therapeutics, Inc. $1,560.00 11/14/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
SRP-9001-305 No dispute reported 06/30/2026 1223614393
Principal investigator 1 Sarepta Therapeutics, Inc. $1,560.00 11/14/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
SRP-9001-305 No dispute reported 06/30/2026 1223614395
Principal investigator 1 Sarepta Therapeutics, Inc. $630.00 11/14/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
SRP-9001-305 No dispute reported 06/30/2026 1223614397
Principal investigator 1 Sarepta Therapeutics, Inc. $1,560.00 11/14/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
SRP-9001-305 No dispute reported 06/30/2026 1223614399
Principal investigator 1 Sarepta Therapeutics, Inc. $1,260.00 11/14/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
SRP-9001-305 No dispute reported 06/30/2026 1223614401
Principal investigator 1 PFIZER INC. $14,300.04 11/07/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
A PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PF 06939926 FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY No dispute reported 06/30/2026 1228820684
Principal investigator 1 Sarepta Therapeutics, Inc. $14.40 11/04/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
SRP-9001-305 No dispute reported 06/30/2026 1223616096
Principal investigator 1 Sarepta Therapeutics, Inc. $120.68 11/04/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
SRP-9001-305 No dispute reported 06/30/2026 1223616098
Principal investigator 1 PFIZER INC. $4,869.90 11/01/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
LONGTERM FOLLOWUP SAFETY AND EFFICACY STUDY IN PARTICIPANTS WITH DUCHENNE MUSCULAR DYSTROPHY WHO HAVE RECEIVED FORDADISTROGENE MOVAPARVOVEC IN A PRECEDING CLINICAL STUDY No dispute reported 06/30/2026 1228819332
Principal investigator 1 PFIZER INC. $6,935.87 10/30/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
A PHASE 1B MULTICENTER OPENLABEL SINGLE ASCENDING DOSE STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF PF06939926 IN AMBULATORY AND NONAMBULATORY SUBJECTS WITH DUCHENNE MUSCULAR DYSTROPHY No dispute reported 06/30/2026 1228814134
Principal investigator 1 PFIZER INC. $5,658.51 10/30/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
A PHASE 1B MULTICENTER OPENLABEL SINGLE ASCENDING DOSE STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF PF06939926 IN AMBULATORY AND NONAMBULATORY SUBJECTS WITH DUCHENNE MUSCULAR DYSTROPHY No dispute reported 06/30/2026 1228814139
Principal investigator 1 PFIZER INC. $495.16 10/30/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
A PHASE 1B MULTICENTER OPENLABEL SINGLE ASCENDING DOSE STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF PF06939926 IN AMBULATORY AND NONAMBULATORY SUBJECTS WITH DUCHENNE MUSCULAR DYSTROPHY No dispute reported 06/30/2026 1228814152
Principal investigator 1 PFIZER INC. $5,903.10 10/25/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
LONGTERM FOLLOWUP SAFETY AND EFFICACY STUDY IN PARTICIPANTS WITH DUCHENNE MUSCULAR DYSTROPHY WHO HAVE RECEIVED FORDADISTROGENE MOVAPARVOVEC IN A PRECEDING CLINICAL STUDY No dispute reported 06/30/2026 1228825924
Principal investigator 1 PFIZER INC. $15,813.56 10/02/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
A PHASE 1B MULTICENTER OPENLABEL SINGLE ASCENDING DOSE STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF PF06939926 IN AMBULATORY AND NONAMBULATORY SUBJECTS WITH DUCHENNE MUSCULAR DYSTROPHY No dispute reported 06/30/2026 1228814125
Principal investigator 1 PFIZER INC. $5,197.50 09/29/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
A PHASE 1B MULTICENTER OPENLABEL SINGLE ASCENDING DOSE STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF PF06939926 IN AMBULATORY AND NONAMBULATORY SUBJECTS WITH DUCHENNE MUSCULAR DYSTROPHY No dispute reported 06/30/2026 1228821204
Principal investigator 1 PFIZER INC. $4,662.00 09/10/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
A PHASE 1B MULTICENTER OPENLABEL SINGLE ASCENDING DOSE STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF PF06939926 IN AMBULATORY AND NONAMBULATORY SUBJECTS WITH DUCHENNE MUSCULAR DYSTROPHY No dispute reported 06/30/2026 1228821211
Principal investigator 1 PFIZER INC. $1,386.00 09/10/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
A PHASE 1B MULTICENTER OPENLABEL SINGLE ASCENDING DOSE STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF PF06939926 IN AMBULATORY AND NONAMBULATORY SUBJECTS WITH DUCHENNE MUSCULAR DYSTROPHY No dispute reported 06/30/2026 1228821216
Principal investigator 1 PFIZER INC. $4,158.00 09/10/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
A PHASE 1B MULTICENTER OPENLABEL SINGLE ASCENDING DOSE STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF PF06939926 IN AMBULATORY AND NONAMBULATORY SUBJECTS WITH DUCHENNE MUSCULAR DYSTROPHY No dispute reported 06/30/2026 1228821222
Principal investigator 1 PTC Therapeutics, Inc. $640.71 08/29/2025 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
AN OPEN-LABEL, SAFETY STUDY FOR ATALUREN (PTC124) PATIENTS WITH NONSENSE MUTATION DYSTROPHINOPATHY No dispute reported 06/30/2026 1249092773
Principal investigator 1 Alexion Pharmaceuticals, Inc. $9,664.00 07/18/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
A Phase 3, Randomized, Double blind, Placebo controlled, Parallel, Multicenter Study to Evaluate the Safety and Efficacy of ALXN1720 in Adults with Generalized Myasthenia Gravis No dispute reported 06/30/2026 1185547163
Recipient PFIZER INC. $780.00 07/10/2025 Covered Recipient Physician PF06755347 CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228802374
Principal investigator 1 Sarepta Therapeutics, Inc. $58.88 07/09/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
SRP-9001-305 No dispute reported 06/30/2026 1223612421
Principal investigator 1 Sarepta Therapeutics, Inc. $8.10 06/30/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
SRP-9001-305 No dispute reported 06/30/2026 1223613021
Principal investigator 1 Sarepta Therapeutics, Inc. $1.20 06/30/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
SRP-9001-305 No dispute reported 06/30/2026 1223613023
Principal investigator 1 Sarepta Therapeutics, Inc. $0.88 06/30/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
SRP-9001-305 No dispute reported 06/30/2026 1223613025
Principal investigator 1 Sarepta Therapeutics, Inc. $0.92 06/30/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
SRP-9001-305 No dispute reported 06/30/2026 1223613027
Principal investigator 1 Sarepta Therapeutics, Inc. $0.68 06/30/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
SRP-9001-305 No dispute reported 06/30/2026 1223613029
Principal investigator 1 Sarepta Therapeutics, Inc. $1.44 06/30/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
SRP-9001-305 No dispute reported 06/30/2026 1223613031
Principal investigator 1 Sarepta Therapeutics, Inc. $2.06 06/30/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
SRP-9001-305 No dispute reported 06/30/2026 1223613033
Principal investigator 1 Sarepta Therapeutics, Inc. $32.54 06/30/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
SRP-9001-305 No dispute reported 06/30/2026 1223613035
Principal investigator 1 Sarepta Therapeutics, Inc. $0.56 06/30/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
SRP-9001-305 No dispute reported 06/30/2026 1223613037
Principal investigator 1 Sarepta Therapeutics, Inc. $8.70 06/30/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
SRP-9001-305 No dispute reported 06/30/2026 1223613039
Principal investigator 1 Sarepta Therapeutics, Inc. $0.12 06/30/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
SRP-9001-305 No dispute reported 06/30/2026 1223613041
Principal investigator 1 Sarepta Therapeutics, Inc. $13.89 06/30/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
SRP-9001-305 No dispute reported 06/30/2026 1223613043
Principal investigator 1 Sarepta Therapeutics, Inc. $1.66 06/30/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
SRP-9001-305 No dispute reported 06/30/2026 1223613045
Principal investigator 1 PFIZER INC. $26,004.83 06/04/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
A PHASE 1B MULTICENTER OPENLABEL SINGLE ASCENDING DOSE STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF PF06939926 IN AMBULATORY AND NONAMBULATORY SUBJECTS WITH DUCHENNE MUSCULAR DYSTROPHY No dispute reported 06/30/2026 1228844304
Principal investigator 1 PTC Therapeutics, Inc. $3,276.00 05/19/2025 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
AN OPEN-LABEL, SAFETY STUDY FOR ATALUREN (PTC124) PATIENTS WITH NONSENSE MUTATION DYSTROPHINOPATHY No dispute reported 06/30/2026 1249092767
Principal investigator 1 Sarepta Therapeutics, Inc. $711.90 05/15/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
SRP-9001-301 No dispute reported 06/30/2026 1223615659
Principal investigator 1 PTC Therapeutics, Inc. $1,275.75 04/30/2025 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
AN OPEN-LABEL, SAFETY STUDY FOR ATALUREN (PTC124) PATIENTS WITH NONSENSE MUTATION DYSTROPHINOPATHY No dispute reported 06/30/2026 1249092763
Principal investigator 1 Sarepta Therapeutics, Inc. $3,908.42 04/30/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
SRP-9001-305 No dispute reported 06/30/2026 1223613875
Recipient Novartis Pharmaceuticals Corporation $3,876.87 04/25/2025 Covered Recipient Physician RESTORE No dispute reported 06/30/2026 1190293203
Principal investigator 1 Sarepta Therapeutics, Inc. $2,079.00 04/17/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
SRP-9001-301 No dispute reported 06/30/2026 1223613877
Principal investigator 1 Sarepta Therapeutics, Inc. $10,962.00 04/17/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
SRP-9001-301 No dispute reported 06/30/2026 1223613879
Principal investigator 1 Sarepta Therapeutics, Inc. $1,260.00 04/17/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
SRP-9001-301 No dispute reported 06/30/2026 1223613881
Principal investigator 1 Sarepta Therapeutics, Inc. $2,520.00 04/17/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
SRP-9001-301 No dispute reported 06/30/2026 1223613883
Principal investigator 1 Sarepta Therapeutics, Inc. $55.44 04/17/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
SRP-9001-301 No dispute reported 06/30/2026 1223613885
Principal investigator 1 Sarepta Therapeutics, Inc. $7,812.00 04/17/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
SRP-9001-301 No dispute reported 06/30/2026 1223613887
Principal investigator 1 Sarepta Therapeutics, Inc. $3,150.00 04/17/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
SRP-9001-301 No dispute reported 06/30/2026 1223613889
Principal investigator 1 Sarepta Therapeutics, Inc. $1,890.00 04/17/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
SRP-9001-301 No dispute reported 06/30/2026 1223613891
Principal investigator 1 Sarepta Therapeutics, Inc. $693.00 04/17/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
SRP-9001-301 No dispute reported 06/30/2026 1223613893
Principal investigator 1 Sarepta Therapeutics, Inc. $207.90 04/17/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
SRP-9001-301 No dispute reported 06/30/2026 1223613895
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,248.00 04/14/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
ConTTRibute: A Global Observational Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis) No dispute reported 06/30/2026 1215516809
Principal investigator 1 Biogen, Inc. $9,072.00 04/02/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
An Open-Label Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of Multiple Doses of ISIS 396443 Delivered Intrathecally to Subjects With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy No dispute reported 06/30/2026 1236947022
Principal investigator 1 Sarepta Therapeutics, Inc. $1,092.18 03/25/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
4045-301 No dispute reported 06/30/2026 1223614467
Principal investigator 1 Sarepta Therapeutics, Inc. $10,818.38 03/18/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
4045-301 No dispute reported 06/30/2026 1223614465
Recipient Novartis Pharma AG $347.75 03/15/2025 Covered Recipient Physician COAV101A12001 No dispute reported 06/30/2026 1248109805
Principal investigator 1 Sarepta Therapeutics, Inc. $12,164.04 03/11/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
4045-301 No dispute reported 06/30/2026 1223614463
Principal investigator 1 Sarepta Therapeutics, Inc. $909.72 03/11/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
4045-301 No dispute reported 06/30/2026 1223614475
Principal investigator 1 Sarepta Therapeutics, Inc. $10,424.13 03/11/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
4045-301 No dispute reported 06/30/2026 1223614477
Principal investigator 1 Sarepta Therapeutics, Inc. $63,678.79 03/11/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
4045-301 No dispute reported 06/30/2026 1223614479
Principal investigator 1 Sarepta Therapeutics, Inc. $31,839.39 03/11/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
4045-301 No dispute reported 06/30/2026 1223614481
Principal investigator 1 Sarepta Therapeutics, Inc. $136,570.14 03/04/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
4045-301 No dispute reported 06/30/2026 1223614461
Principal investigator 1 PTC Therapeutics, Inc. $640.71 02/27/2025 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
AN OPEN-LABEL, SAFETY STUDY FOR ATALUREN (PTC124) PATIENTS WITH NONSENSE MUTATION DYSTROPHINOPATHY No dispute reported 06/30/2026 1249092759
Principal investigator 1 Sarepta Therapeutics, Inc. $130.92 02/18/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
SRP-9001-305 No dispute reported 06/30/2026 1223615450
Principal investigator 1 Sarepta Therapeutics, Inc. $2,322.21 01/29/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
SRP-9001-305 No dispute reported 06/30/2026 1223615446
Principal investigator 1 Sarepta Therapeutics, Inc. $1,629.61 01/29/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
SRP-9001-305 No dispute reported 06/30/2026 1223615448
Principal investigator 1 UCB SA $7,833.40 01/27/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
A PHASE 3B, MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND EFFICACY OF ZILUCOPLAN IN PARTICIPANTS WITH GENERALIZED MYASTHENIA GRAVIS SWITCHING FROM INTRAVENOUS COMPLEMENT COMPONENT 5 INHIBITORS TO SUBCUTANEOUS ZILUCOPLAN No dispute reported 06/30/2026 1246659539
Principal investigator 1 Sarepta Therapeutics, Inc. $6,120.33 01/23/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
4045-301 No dispute reported 06/30/2026 1223614457
Principal investigator 1 Sarepta Therapeutics, Inc. $17,125.25 01/23/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
4045-301 No dispute reported 06/30/2026 1223614459
Principal investigator 1 Sarepta Therapeutics, Inc. $11,645.73 01/23/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
4045-301 No dispute reported 06/30/2026 1223614469
Principal investigator 1 Biogen, Inc. $8,568.00 01/16/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
An Open-Label Extension Study for Patients With Spinal Muscular AtrophyWho Previously Participated in Investigational Studies of ISIS 396443 No dispute reported 06/30/2026 1236947632
Principal investigator 1 Sarepta Therapeutics, Inc. $642.60 01/16/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
4045-301 No dispute reported 06/30/2026 1223614471
Principal investigator 1 Sarepta Therapeutics, Inc. $4,536.00 01/16/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
4045-301 No dispute reported 06/30/2026 1223614473
Principal investigator 1 Alnylam Pharmaceuticals Inc. $851.00 01/15/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
ConTTRibute: A Global Observational Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis) No dispute reported 06/30/2026 1215516803
Principal investigator 1 VERTEX PHARMACEUTICALS INCORPORATED $2,460.00 01/01/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
A Phase 1/2, Randomized, Double-blind, Placebo?controlled Single- and Multiple?dose Escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VX?670 in Adult Subjects with Myotonic Dystrophy Type 1 No dispute reported 06/30/2026 1214124058